AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02111642 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Online risk calculator
Description: A new online risk calculator tool has been developed to predict a woman's individual risk of developing de novo stress urinary incontinence after prolapse surgery. This validated tool has been shown to outperform preoperative prolapse reduction stress testing results and expert predictions when providing risk assessment of de novo stress urinary incontinence after vaginal prolapse surgery. After inputting individual patient characteristics, including patient age, body mass index, number of vaginal deliveries, presence or absence of urgency urinary incontinence and diabetes, and prolapse reduction stress testing results if available, this tool calculates the theoretical risk of postoperative de novo stress urinary incontinence both with and without an anti-incontinence procedure.
Study NCT02111642 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online risk calculator
Description: A new online risk calculator tool has been developed to predict a woman's individual risk of developing de novo stress urinary incontinence after prolapse surgery. This validated tool has been shown to outperform preoperative prolapse reduction stress testing results and expert predictions when providing risk assessment of de novo stress urinary incontinence after vaginal prolapse surgery. After inputting individual patient characteristics, including patient age, body mass index, number of vaginal deliveries, presence or absence of urgency urinary incontinence and diabetes, and prolapse reduction stress testing results if available, this tool calculates the theoretical risk of postoperative de novo stress urinary incontinence both with and without an anti-incontinence procedure.
Study NCT03836391 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nudge
Description: Nudge is a smartphone-app-based micro-randomized trial that tests the effect of 7 intervention message types based on behavior change techniques on daily goal attainment. Participants have three daily goals: weigh daily, red foods goal, and active minutes goal.
Study NCT03424252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDL169
Description: Cystic Fibrosis Transmembrane Regulator (CFTR) corrector
Study NCT03620864 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor Control Exercise Plus Neurodynamic Intervention
Description: Patients will receive 8 sessions of motor control exercise program of 30 min duration for 4 weeks, twice per week. Exercises will be demonstrated to the participants by an experienced physical therapist. On each session, the therapist will correct each subject personally. Participants will be asked for practicing the exercises at home once daily for 20 minutes over the 8-week intervention period. The motor control exercise program will consist of a progression from isolated contraction of the transversus abdominis and/or isolated contraction of the multifidi to combined contraction of both transversus abdominis in different positions from supine or prone to bridging or four-point kneeling. In addition, participants allocated to the neurodynamic group will also receive a nerve neurodynamic slider intervention targeting the main trunk of the sciatic nerve of the affected side during al treatment sessions (n=8).
Study NCT03540836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relacorilant (3x100 mg softgel capsules)
Description: A single relacorilant 300mg dose (3x100 mg softgel capsules) will be given once on Day 1 of one of three treatment periods.
Study NCT03540836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relacorilant (3x100 mg hard-shell capsules)
Description: A single relacorilant 300mg dose (3x100 mg hard-shell capsules) will be given once on Day 1 of one of three treatment periods.
Study NCT03540836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relacorilant (6x50mg hard-shell capsules)
Description: A single relacorilant 300mg dose (6x50mg hard-shell capsules) will be given once on Day 1 of one of three treatment periods.
Study NCT03900403 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walnut Intake
Description: 40g of daily walnut intake for 12 weeks
Study NCT01073332 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Arginine antioxidant supplements
Description: The proprietary supplement Niteworks® was manufactured by Herbalife International Inc. (Century City, California, USA). Each serving contained 5.2g L-arginine in a proprietary blend with L-citrulline, 500mg ascorbic acid, 400IU vitamin E, 400ug folic acid, 300mg L-taurine, and 10mg alpha lipoic acid in a lemon-flavored powder form. One serving of supplement powder was mixed with 8 oz of water, administered at bedtime based on the rationale that nitric oxide levels are lowest during sleep due to inactivity, lack of food and low blood pressure.
Study NCT01073332 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo group received a powder with all active ingredients replaced with M-100 maltodextrin.
Study NCT01323426 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Periurethral injection
Description: Periurethral injection of autologous muscle fibers
Study NCT00549172 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Operative (partial arthroscopy)
Description: Partial arthroscopic resection of degenerative rupture of the medial meniscus
Study NCT03218501 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SK-1405 low dose
Description: SK-1405 low dose is to be administered orally once daily for 2 weeks
Study NCT00549172 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Conservative (diagnostic arthroscopy)
Description: Diagnostic arthroscopy
Study NCT00910793 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Inuvair
Description: 6 µg formoterol and 100 µg beclometasone dipropionate combination spray pMDI aerosol
Study NCT03757208 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: carbohydrate rich drink
Description: The carbohydrate rich drink (CHD) group received oral carbohydrate (200 ml) 2-3 h before surgery,
Study NCT03464656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fairhaven Pro for men
Description: Fairhaven Pro for men~The antioxidant formula (Fairhaven Health) contains:~* B12 (1000 mcg)~* Zinc (30 mg)~* Selenium (140 mcg)~* Arginine (350 mg)~* L-carnitine tartrate (2000 mg) , providing 1,340 mg of L-carnitine~* CoQ10 (200 mg)~* Vitamin C (120 mg) and Vitamin E (200 IU)
Study NCT03464656 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Semen analysis
Description: Full semen analysis according to WHO semen laboratory manual 5th edition will be done pre and 3 months post-treatment.~After complete liquefaction, each sample was evaluated for both macroscopic parameters such as color, pH, ejaculate volume, age of the sample and viscosity. An aliquot of the sample was examined for sperm concentration, total sperm count, total and progressive motility and sperm morphology using the WHO fifth edition guidelines (WHO, 2010). Semen analysis was done manually using a hemocytometer. Sperm motility was assessed and categorized as progressive or non-progressive. Morphology was assessed by a single experienced technician using the Diff-Quik staining protocol. Kruger's strict criteria were used for morphology assessment with 4% normal morphology as a cut-off (WHO, 2010).
Study NCT03464656 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Sperm DNA fragmentation
Description: Sperm DNA fragmentation was evaluated using the Halosperm kit from Halotech DNA, S.L. (Madrid, Spain) as per manufacturer instructions. The method is based on the sperm chromatin dispersion test (Fernández et al., 2003). A minimum of 500 spermatozoa were scored and reported as percentage of sperm with spermatozoa with fragmented DNA. Normal value is measure at a cut-off value of more than 30%
Study NCT03464656 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Static Oxidation reduction potential in semen
Description: Oxidative stress was assessed by measuring the static oxidation-reduction potential (sORP) of neat liquefied semen samples using the MiOXSYSTM System (Aytu Bioscience, Inc., Englewood, USA). This is a galvanostatic measure of the electron transfer from reductants (antioxidants) to oxidants under a steady low voltage reducing current. Thus, providing an aggregate measure of all current oxidant activity and antioxidant activity in a sample. Higher sORP values (millivolts, mV) indicate a higher oxidant activity relative to the antioxidant activity and therefore greater state of oxidative stress.
Study NCT00829907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORM-12741
Description: Single dose as a capsule, oral administration
Study NCT00814775 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fastrach Laryngeal Mask
Description: Intubation of difficult airway using Fastrach Laryngeal Mask
Study NCT00814775 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CTrach Laryngeal Mask
Description: CTrach Laryngeal Mask intubation
Study NCT05422807 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: BFST for Teens with Type 2 Diabetes
Description: 12 (90 minute sessions) over 6 months of Behavioral Family Systems Therapy (BFST), delivered by a Licensed clinical social worker. BFST consists of 4 components: problem-solving, communication skills training, cognitive restructuring, and functional and structural family therapy.
Study NCT03579784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 80 mg/m2 mg iv on D1, D8, D15 Every 4 weeks
Study NCT03579784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib 150mg bid on D1-28 Every 4 weeks
Study NCT03579784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab 1.5 g iv on D1 Every 4 weeks
Study NCT03358719 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DEC-205/NY-ESO-1 Fusion Protein CDX-1401
Description: Given intracutaneously
Study NCT03358719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Given IV
Study NCT03358719 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03358719 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT03358719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poly ICLC
Description: Given SC
Study NCT02595723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenytoin 200 mg capsule
Description: Phenytoin oral capsule was initiated on Day 1 and administered at 200 mg twice/day for four consecutive days (Days 1 - 4).
Study NCT02595723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Megestrol 800 mg liquid
Description: Liquid megestrol 800 mg/was initiated on Day 2 and administered at 09:00 for three consecutive days (Days 2 - 4).
Study NCT03218501 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is to be administered orally once daily for 2 weeks
Study NCT01008644 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water
Description: The subjects will drink tap water for 2 hours, volume calculated according to weight: 20ml/kg/hour.
Study NCT02595723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenytoin-matched Placebo capsule
Description: Phenytoin-matched oral Placebo capsule was initiated on Day 1 and administered for four consecutive days (Days 1 - 4).
Study NCT02595723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Megestrol-matched liquid Placebo
Description: Megestrol-matched liquid placebo was initiated on Day 2 and administered at 09:00 for three consecutive days (Days 2 - 4).
Study NCT01565070 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Biofreeze
Description: Use of Biofreeze ointment
Study NCT01565070 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Use of placebo ointment
Study NCT01307475 — intervention group
Intervention type: OTHER
Intervention: PTSD Checklist-Specific
Description: Completed by patients before clinical examination; it is a 17-item survey listing of symptoms of posttraumatic stress disorder.
Study NCT04295824 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Skin imaging and Skin biopsy
Description: Imaging includes:~* Structural Optical Coherence Tomography (OCT) - Skin thickness/roughness.~* Angiographic OCT- Vessel depth/morphology.~* Polarisation-sensitive OCT - Tissue birefringence / collagen index.~* Skin biopsies will be taken from the same volar forearm site as the imaging is performed.
Study NCT01307475 — intervention group
Intervention type: OTHER
Intervention: Modified Flanagan Quality of Life Scale
Description: Completed by patients before clinical examination; it is a 16-item survey designed for use in persons with chronic illness.
Study NCT01307475 — intervention group
Intervention type: OTHER
Intervention: Center for Epidemiologic Studies Depression Scale
Description: Completed by patients before clinical examination; it is a 20-item survey that asks about depressive feelings and behaviours in the past week.
Study NCT01008644 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline 3%
Description: The subjects will receive saline 3% intravenously for 2 hours, the volume calculated as 0.1 ml/kg/min
Study NCT01143324 — intervention group
Intervention type: DEVICE
Intervention: MAST™ procedure
Description: Single or double level instrumented fusion receiving the CD Horizon® Spinal System using PLIF or TLIF techniques via a MAST™ procedure.
Study NCT03136575 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Qigong
Description: a 30 minutes exercise program, 3 times a week and lasts for 6 weeks during radiotherapy course
Study NCT03136575 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Wait-list control
Description: patients enrolled in this group are informed orally to have exercise only and are arranged in a waiting list
Study NCT01950663 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RETeval
Description: RETeval is a new handheld device intended to detect vision threatening diabetic retinopathy by measuring the response of the retina to a flash of light.
Study NCT03811938 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low voltage ablation
Description: Catheter ablation of low voltage areas in the left atrium and catheter ablation aiming for the electrical isolation of the pulmonary veins.
Study NCT01307475 — intervention group
Intervention type: OTHER
Intervention: Functional Enquiry Form
Description: Completed by patients before clinical examination; it is a checklist of medical problems.
Study NCT01307475 — intervention group
Intervention type: OTHER
Intervention: Strength, Joint ROM, Girth and Length Measurements
Description: Completed during the clinical examination by the researchers, it is a structured approach to evaluation of muscles, joints, arms, thighs, and legs.
Study NCT01307475 — intervention group
Intervention type: OTHER
Intervention: Study Physical Examination
Description: Completed during the clinical examination by the researchers, it is a structured approach to a full physical examination, minus breasts, genitalia or rectum.
Study NCT01307475 — intervention group
Intervention type: OTHER
Intervention: PTSD, Depression, and FSS-Focused Examination
Description: Completed during the clinical examination by the researchers, it is a structured approach to evaluation of symptoms, signs, and perceptions that may be related to FSS, PTSS, or depressive problems.
Study NCT01307475 — intervention group
Intervention type: OTHER
Intervention: Freeman-Sheldon Specific Quality of Life Survey
Description: Completed after data analysis from the existing surveys and clinical examination, it will be a specific quality of life survey developed and tested during the study; it will take into consideration individual's total health outcome.
Study NCT01307475 — intervention group
Intervention type: OTHER
Intervention: Lactate, Glucose, and Adenosine Triphosphate Blood Levels
Description: Completed during the clinical examination by the researchers, lactate, glucose, and free and total adenosine triphosphate blood levels are determined at rest.
Study NCT00707070 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: efalizumab plus placebo
Description: 1 mg/kg/week subcutaneous for 24 weeks
Study NCT00707070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: efalizumab plus acitretin
Description: 1 mg/Kg/week for 24 weeks plus oral acitretin 0.4 mg/kg/day
Study NCT03132337 — intervention group
Intervention type: OTHER
Intervention: Serial Blood Draws
Description: Day 0 and Day 3 blood draw for SOS biomarkers. If subject develops SOS blood draw prior to dose of Defibrotide, Day 14 after Defibrotide and Day 21 after Defibrotide.
Study NCT01509963 — intervention group
Intervention type: OTHER
Intervention: no intervention : measure of score
Description: To provide probability of non sentinel lymph node metastasis in case of metastatic lymph node according to MSKCC nomogram and Tenon score.
Study NCT02777671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 2-093
Study NCT02777671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gliclazide
Description: tablets containing gliclazide 80 mg (Diamicron® 80 mg)
Study NCT01972750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dovitinib
Description: daily oral intake of capsule
Study NCT00004259 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BCNU 80mg/m2
Description: BCNU 80 mg/m2 will be administered as an intravenous infusion on days 1, 2, and 3 of the first week of radiotherapy and on days 56, 57, and 58, then every eight weeks for four more cycles for a total of 6 cycles (maximum BCNU dose 1440 mg/m2).
Study NCT00004259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMZ 200mg/m2
Description: 200 mg/m2 orally on days 1-5 of the first week of radiotherapy. Repeat every 28 days for a total of 12 cycles.
Study NCT00004259 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: 1.8 Gy fractions (to isocenter), 1 fraction per day, 5 days per week to a dose of 59.4 Gy in 33 fractions.
Study NCT00004259 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Description: 1.8 Gy fractions (to isocenter), 1 fraction per day, 5 days per week to a dose of 59.4 Gy in 33 fractions.
Study NCT00004259 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CCNU
Description: CCNU at 130 mg/m2 orally every 8 weeks for a total of 6 cycles. Administered on day 1 of the first week of radiotherapy and on day 56, then administered every 8 weeks for four more cycles for a total of 6 cycles.
Study NCT00004259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCNU 150mg/m2
Description: BCNU 150 mg/m2 will be administered as an intravenous infusion on day 5 of radiotherapy, and it will be repeated every eight weeks for a total of six cycles (maximum total BCNU dose 900 mg/m2).
Study NCT00004259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCNU 200mg/m2
Description: BCNU 200 mg/m2 will be administered as an intravenous infusion on day 1 of radiotherapy and will be repeated every six weeks for a total of 6 cycles (maximum BCNU dose 1200 mg/m2).
Study NCT00004259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMZ 150mg/m2 six 6-week cycles
Description: 150 mg/m2 orally on days 1-5 of the first week of radiotherapy. Repeat for a total of six 6-week cycles
Study NCT00004259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMZ 150mg/m2 six 8-week cycles
Description: 150 mg/m2 orally on days 1-5 of the first week of radiotherapy. Repeat for a total of six 8-week cycles
Study NCT03134872 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SHR-1210
Description: SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody.
Study NCT03134872 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin
Study NCT03134872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin
Study NCT03134872 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Pemetrexed
Study NCT03134872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed
Study NCT02765568 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training
Description: Participants will complete supervised exercise sessions. Participants will attend on-site high-intensity interval training two times weekly for 12 weeks
Study NCT02765568 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate Intensity Continuous Exercise Training
Description: Participants will complete supervised exercise sessions. Moderate-intensity continuous exercise training will follow cardiovascular rehabilitation guidelines. Participants will attend on-site moderate-intensity continuous exercise training two times weekly for 12 weeks.
Study NCT02765568 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nordic Walking
Description: Participants will complete supervised exercise sessions. Participants will attend on-site Nordic walking training two times weekly for 12 weeks
Study NCT00865826 — intervention group
Intervention type: OTHER
Intervention: Standardized diagnostic evaluation
Description: Participants will undergo a diagnostic evaluation for TB at study entry